Binary Solid Lipid Nanosuspension Containing Cefixime: Preparation, Characterization and Comparative In-vivo Evaluation

  1. Mahwish KamranORCID Logo,
  2. Mir Azam KhanORCID Logo,
  3. Maqsood ur RehmanORCID Logo,
  4. Muhammad Shafique,
  5. Abdullah KhanORCID Logo and
  6. Sajjad AhmadORCID Logo

Submitting author affiliation: University of Malakand, Chakdara Dir Lower, Pakistan

Beilstein Arch. 2019, 2019109. doi:10.3762/bxiv.2019.109.v1

Published 26 Sep 2019

  • Preprint

Abstract

Current study focused on resolution of poor oral bioavailability issues of cefixime through fabrication of its freeze dried binary solid lipid nano particles (SLNs). The nano formulation fabricated via hot melt encapsulation (HME) method was optimized using numerous formulation variables. Optimized nano formulation (CFX-4) showed particle size 206.6±2.3 nm, polydispersity index (PDI) 0.271±0.03, zeta potential (ZP) -30.7±3.1 mV, encapsulation efficiency (EE%) 88.2±2.3% along with drug loading capacity (DLC%) 4.83±0.16%. Micrograph of scanning electron microscopy (SEM) represented spherical shaped particles. Reduction in drug’s crystalline nature was acknowledged through differential scanning calorimetry (DSC) and x-ray powder diffraction (P-XRD) analysis. Drug-excepient compatibility was established through fourier transform infrared spectroscopic (FT-IR) analysis. During in-vitro studies; sustained drug release was favored by increased drug payload. Stability studies exposed that refrigerated temperature imparts maximum stability to binary SLNs. In-vivo pharmacokinetic studies revealed the desired enhancement in oral bioavailability compared to the marketed product (Cefiget®). Presented investigations established the dominance of binary SLNs for improvement of oral bioavailability with sustained drug release characteristics. Based on the reported outcomes, binary SLNs can be employed as an advanced drug delivery system for other hydrophobic drugs.

Keywords: Hot melt encapsulation; binary solid lipid nano particles; bioavailability; in-vitro; in-vivo study

How to Cite

When a peer-reviewed version of this preprint is available in the Beilstein Journals, this information will be updated in the information box above. If no peer-reviewed version is available, please cite this preprint using the following information:

Kamran, M.; Khan, M. A.; Rehman, M. U.; Shafique, M.; Khan, A.; Ahmad, S. Beilstein Arch. 2019, 2019109. doi:10.3762/bxiv.2019.109.v1

Download Citation
Download RIS (Reference Manager) Download BIB (BIBTEX)

© 2019 Kamran et al.; licensee Beilstein-Institut.
This is an Open Access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0). Please note that the reuse, redistribution and reproduction in particular requires that the authors and source are credited.
The license is subject to the Beilstein Archives terms and conditions: (https://www.beilstein-archives.org/xiv/terms)

Other Beilstein-Institut Open Science Activities

Logo
Logo
Logo
Symposia